GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (STU:BJX1) » Definitions » Cash And Cash Equivalents

BioLife Solutions (STU:BJX1) Cash And Cash Equivalents : €61.92 Mil (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is BioLife Solutions Cash And Cash Equivalents?

BioLife Solutions's quarterly cash and cash equivalents increased from Sep. 2024 (€21.60 Mil) to Dec. 2024 (€91.09 Mil) but then stayed the same from Dec. 2024 (€91.09 Mil) to Mar. 2025 (€61.92 Mil).

BioLife Solutions's annual cash and cash equivalents increased from Dec. 2022 (€18.35 Mil) to Dec. 2023 (€25.58 Mil) and increased from Dec. 2023 (€25.58 Mil) to Dec. 2024 (€91.09 Mil).


BioLife Solutions Cash And Cash Equivalents Historical Data

The historical data trend for BioLife Solutions's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions Cash And Cash Equivalents Chart

BioLife Solutions Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74.31 61.83 18.35 25.58 91.09

BioLife Solutions Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.32 20.45 21.60 91.09 61.92

BioLife Solutions Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


BioLife Solutions  (STU:BJX1) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


BioLife Solutions Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLife Solutions Business Description

Traded in Other Exchanges
Address
3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

BioLife Solutions Headlines

No Headlines